Author: Eric Anthony Coomes; Hourmazd Haghbayan
Title: Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis Document date: 2020_4_3
ID: nadcsiii_28
Snippet: One study examined the clinical impact of tocilizumab on severe COVID-19 disease.43 In a non-randomized, open-label, clinical trial, 21 patients with severe or critical COVID-19 were treated with tocilizumab. Mean age was 56.8 years and 14% of patients were female; critical disease was identified in four patients (19%). All patients received institutional standard of care including lopinavir and methylprednisolone, as well as tocilizumab 400 mg i.....
Document: One study examined the clinical impact of tocilizumab on severe COVID-19 disease.43 In a non-randomized, open-label, clinical trial, 21 patients with severe or critical COVID-19 were treated with tocilizumab. Mean age was 56.8 years and 14% of patients were female; critical disease was identified in four patients (19%). All patients received institutional standard of care including lopinavir and methylprednisolone, as well as tocilizumab 400 mg intravenously in one to two doses. Eighteen patients (85.7%) received tocilizumab once, and three patients (14.3%)
Search related documents:
Co phrase search for related documents- care institutional standard and institutional standard: 1, 2, 3, 4, 5, 6, 7
- care institutional standard and open label: 1
- clinical impact and critical disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- clinical impact and critical severe: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- clinical impact and mean age: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- clinical impact and open label: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- clinical impact and tocilizumab clinical impact: 1, 2
- clinical trial and critical disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- clinical trial and critical severe: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51
- clinical trial and eighteen patient: 1, 2
- clinical trial and institutional standard: 1, 2, 3, 4, 5
- clinical trial and mean age: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- clinical trial and non randomized open label: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- clinical trial and non randomized open label clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9
- clinical trial and open label: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- clinical trial and tocilizumab receive: 1, 2, 3
- clinical trial and tocilizumab treat: 1, 2
- critical disease and mean age: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67
- critical disease and open label: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date